Liver Resection
Conditions
Keywords
Watson artificial intelligence, hepatocellular carcinoma, surgical decisions
Brief summary
The aim of this study was to evaluate the surgical decisions of Watson artificial intelligence in patients with hepatocellular carcinoma.
Detailed description
Hepatectomy is an effective treatment for patients with hepatocellular carcinoma, but liver failure after hepatectomy may lead to increased postoperative mortality. Therefore, it is very important to make preoperative surgical decisions, evaluate the safety of the operation and identify which patients are likely to suffer from liver failure. The artificial intelligence platform developed by IBM Watson for Watson tumor treatment decisions can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.
Interventions
OTHERWatson on oncology surgery decision evaluation
Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.
Sponsors
Zhujiang Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. 18 years≤ Age ≤80 years 2. Compling with the diagnosis criteria of complex hepatic carcinoma. 3. Primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled 4. Preoperative liver function is Child - Pugh grade A or B. 5. The patients are volunteered for the study.
Exclusion criteria
1. Patients with mental illness. 2. Patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.) 3. The patients refused to take part in the study. 4. There are other co-existed malignant tumors. 5. Benign liver diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Operative outcomes | intraoperative | Operative outcomes such as operative time, estimated blood loss and blood transfusion were recorded. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative survival | 3 years | Survival after hepatectomy |
Other
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival | 3 years | Survival time without tumor after hepatectomy |
Countries
China
Outcome results
None listed